Literature DB >> 20188249

Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive.

Natalie A Hutnick1, Diane Carnathan, Korey Demers, George Makedonas, Hildegund C J Ertl, Michael R Betts.   

Abstract

Pre-existing immunity to adenovirus (Ad) reduces the efficacy of Ad-based vaccines. The goal of this study was to define the prevalence, magnitude, functionality and phenotype of Ad-specific human T cells directly ex vivo. To study the magnitude of T-cell responses to Ad, we developed a highly reproducible whole Ad vector stimulation assay for use with polychromatic flow cytometry. Ad-specific CD4(+) and CD8(+) T-cells were detected in all 17 human subjects tested and were capable of proliferating upon restimulation. Ad5-specific CD4(+) T cells were primarily monofunctional CD4(+) T cells that produced IL-2, IFN-gamma or TNFalpha and expressed the memory markers CD27 and CD45RO. In contrast, Ad5-specific CD8(+) T cells were more polyfunctional, expressing effector-like combinations of IFN-gamma, MIP1alpha and perforin, and generally lacked CD27 and CD45RO expression. Ad-specific CD4(+) and CD8(+) T-cell responses against chimpanzee-derived AdC6 and AdC7 were found in all subjects, indicating the commonality of cross-serotype reactivity of Ad-specific T cells. This cross-reactivity is due in part to extensive CD4(+) and CD8(+) T-cell recognition of hexon regions conserved between multiple Ad serotypes. The prevalence, cross-reactivity and effector-like functions of Ad-specific T cells in humans may affect the efficacy of Ad vector-based vaccines by eliminating vector infected cells even when rare serotype Ad vectors are employed. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188249      PMCID: PMC2832841          DOI: 10.1016/j.vaccine.2009.10.091

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Overcoming immunity to a viral vaccine by DNA priming before vector boosting.

Authors:  Zhi-yong Yang; Linda S Wyatt; Wing-Pui Kong; Zoe Moodie; Bernard Moss; Gary J Nabel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.

Authors:  Shawn M Sumida; Diana M Truitt; Angelique A C Lemckert; Ronald Vogels; Jerome H H V Custers; Marylyn M Addo; Shahin Lockman; Trevor Peter; Fred W Peyerl; Michael G Kishko; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Myron Essex; Bruce D Walker; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

3.  Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively.

Authors:  J C De Jong; A G Wermenbol; M W Verweij-Uijterwaal; K W Slaterus; P Wertheim-Van Dillen; G J Van Doornum; S H Khoo; J C Hierholzer
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

4.  Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.

Authors:  Danilo R Casimiro; Andrew J Bett; Tong-ming Fu; Mary-Ellen Davies; Aimin Tang; Keith A Wilson; Minchun Chen; Romnie Long; Troy McKelvey; Michael Chastain; Sanjay Gurunathan; Jim Tartaglia; Emilio A Emini; John Shiver
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

5.  Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues.

Authors:  L Crawford-Miksza; D P Schnurr
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

6.  Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells.

Authors:  Ann M Leen; Uluhan Sili; Elio F Vanin; Alan M Jewell; Weidong Xie; Dario Vignali; Pedro A Piedra; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2004-07-20       Impact factor: 22.113

7.  Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele.

Authors:  J Tang; M Olive; K Champagne; N Flomenberg; L Eisenlohr; S Hsu; P Flomenberg
Journal:  Gene Ther       Date:  2004-09       Impact factor: 5.250

8.  Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Authors:  Danilo R Casimiro; Ling Chen; Tong-Ming Fu; Robert K Evans; Michael J Caulfield; Mary-Ellen Davies; Aimin Tang; Minchun Chen; Lingyi Huang; Virginia Harris; Daniel C Freed; Keith A Wilson; Sheri Dubey; De-Min Zhu; Denise Nawrocki; Henryk Mach; Robert Troutman; Lynne Isopi; Donna Williams; William Hurni; Zheng Xu; Jeffrey G Smith; Su Wang; Xu Liu; Liming Guan; Romnie Long; Wendy Trigona; Gwendolyn J Heidecker; Helen C Perry; Natasha Persaud; Timothy J Toner; Qin Su; Xiaoping Liang; Rima Youil; Michael Chastain; Andrew J Bett; David B Volkin; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

Review 9.  T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients.

Authors:  A M Leen; G D Myers; C M Bollard; M H Huls; U Sili; A P Gee; H E Heslop; C M Rooney
Journal:  Ann N Y Acad Sci       Date:  2005-12       Impact factor: 5.691

10.  Host immune responses to chronic adenovirus infections in human and nonhuman primates.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Soumitra Roy; Suryanarayan Somanathan; Lili Wang; James M Wilson
Journal:  J Virol       Date:  2008-12-30       Impact factor: 5.103

View more
  42 in total

1.  Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.

Authors:  H Chen; Z Q Xiang; Y Li; R K Kurupati; B Jia; A Bian; D M Zhou; N Hutnick; S Yuan; C Gray; J Serwanga; B Auma; P Kaleebu; X Zhou; M R Betts; H C J Ertl
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection.

Authors:  M Jeyanathan; N Thanthrige-Don; S Afkhami; R Lai; D Damjanovic; A Zganiacz; X Feng; X-D Yao; K L Rosenthal; M Fe Medina; J Gauldie; H C Ertl; Z Xing
Journal:  Mucosal Immunol       Date:  2015-04-15       Impact factor: 7.313

Review 3.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Adenovirus infections in immunocompetent and immunocompromised patients.

Authors:  Thomas Lion
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 5.  Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo.

Authors:  Natalie A Hutnick; Devin J F Myles; Chaoran Billie Bian; Karuppiah Muthumani; David B Weiner
Journal:  Curr Opin Virol       Date:  2011-09-07       Impact factor: 7.090

6.  Protection of non-human primates against rabies with an adenovirus recombinant vaccine.

Authors:  Z Q Xiang; L Greenberg; H C Ertl; C E Rupprecht
Journal:  Virology       Date:  2014-01-09       Impact factor: 3.616

7.  Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Joseph P Balint; Stephanie Balcaitis; Brigitte Sanders-Beer; Frank R Jones
Journal:  Vaccine       Date:  2011-08-22       Impact factor: 3.641

8.  T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load.

Authors:  Yaowaluck Roshorm; Mathew G Cottingham; Mary-Jane Potash; David J Volsky; Tomáš Hanke
Journal:  Eur J Immunol       Date:  2012-10-16       Impact factor: 5.532

9.  Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.

Authors:  Camilla Patrizia Hrycak; Sonja Windmann; Wibke Bayer
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

10.  Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.

Authors:  Elizabeth S Gabitzsch; Joseph P Balint-Junior; Younong Xu; Stephanie Balcaitis; Brigitte Sanders-Beer; Julie Karl; Kent J Weinhold; Slobodan Paessler; Frank R Jones
Journal:  Vaccine       Date:  2012-10-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.